Exelixis says there is more to come after three stunning deals
CEO George Scangos and dealmaker Fran Heller
George Scangos, President and CEO of Exelixis, re-energized a troubled biotech industry, according to the Wall Street Journal, when he announced earlier this year he had licensed two cancer drugs to French pharmaceutical giant Sanofi-aventis with an upfront payment of USD 140 million.
The news came on the heels of Read more »